The researcher built and trained their generative AI model on thousands of molecules to see which would bind with two COVID-19 protein targets. The four validated molecules still have to clear regulations and clinical trials before they can be turned into drugs, according to a June 28 IBM blog post.
The researchers hope that the study shows how generative AI could be used to expedite the drug discovery process during a public health crisis.
“It took time to develop and validate these methods, but now that we have a working pipeline in place, we can generate results much faster,” Payel Das, PhD, a researcher at IBM Research and study co-senior author, said in the release. “When the next virus emerges, generative AI could be pivotal in the search for new treatments.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
